Skip to main content
. 2021 Dec 8;9(12):1863. doi: 10.3390/biomedicines9121863

Figure 1.

Figure 1

Figure 1

(A) Biomarkers of positive response to immune checkpoint inhibitors in the tumor microenvironment. (B) Biomarkers of poor response to immune checkpoint inhibitors in the tumor. Abbreviations: tumor mutational burden (TMB) programmed death ligand 1 (PD-L1) T cell receptor (TCR) breast cancer gene (BRCA).